Endoglin
-
Subject Areas on Research
- A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
- ALK1 regulates the internalization of endoglin and the type III TGF-β receptor.
- ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration.
- Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.
- Applicability of the Curaçao Criteria for the Diagnosis of Hereditary Hemorrhagic Telangiectasia in the Pediatric Population.
- Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
- Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin?
- Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1.
- Endoglin Mediates Vascular Maturation by Promoting Vascular Smooth Muscle Cell Migration and Spreading.
- Endoglin Targeting: Lessons Learned and Questions That Remain.
- Endoglin deficiency impairs stroke recovery.
- Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage.
- Endoglin interacts with VEGFR2 to promote angiogenesis.
- Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells.
- Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC.
- Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis.
- Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.
- Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development.
- Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms.
- Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1.
- Genetic abnormalities in hereditary hemorrhagic telangiectasia.
- Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations.
- Hereditary hemorrhagic telangiectasia: two distinct ENG deletions in one family.
- Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
- Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth.
- Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
- Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.
- Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
- Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles.
- Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice.
- Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations.
- Predictors of mortality in patients with hereditary hemorrhagic telangiectasia.
- Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
- Regulation of TGF-β receptor hetero-oligomerization and signaling by endoglin.
- SMAD4 mutations found in unselected HHT patients.
- Signaling by the transforming growth factor-beta receptors.
- Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function.
- Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.
- Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
- Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
- The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells.
- The modulation of MSC integrin expression by RGD presentation
- The molecular genetics of hereditary hemorrhagic telangiectasia.
- Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways.
- Transdifferentiation of human endothelial progenitors into smooth muscle cells.
- Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence for a founder effect.
- Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia.
- Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
- Vascular morphogenesis: tales of two syndromes.